Julie Hallet, President at Society of Surgical Ergonomics, shared on X:
“Louder for the people in the back: PanNET is not PDAC
Major postop risk differences:
- 4152 whipple
- PanNET major complications increased x3 vs other indications
- Generic postop data can’t define PanNETs risk-benefit.
Tailor decisions to biology and risks.”
Title: Impact of pathological diagnosis on postoperative outcomes after pancreatoduodenectomy: A nationwide cohort study
Authors: Jacob L. van Dam, Jelle C. van Dongen, Marc G. Besselink, Bert A. Bonsing, Koop Bosscha, Ronald M. van Dam, Sebastiaan Festen, Erwin van der Harst, Ignace H. de Hingh, Geert Kazemier, Mike S. L. Liem, Vincent E. de Meijer, J. Sven D. Mieog, I. Quintus Molenaar, Gijs A. Patijn, Hjalmar C. van Santvoort, George P. van der Schelling, Martijn W. J. Stommel, Fennie Wit, Roeland F. de Wilde, Bas Groot Koerkamp
Read the full article.
You can also explore:
FDA Accepts Daraxonrasib NDA for Review in Previously Treated Metastatic Pancreatic Cancer
